Alpha-N-acetylgalactosaminidase in cancer: diagnostic applications and related treatment strategies.

Abstract

Alpha-N-acetylgalactosaminidase (nagalase), a lysosomal enzyme encoded by the NAGA gene, plays a critical role in the degradation of glycoconjugates, modulation of immune responses, and regulation of vitamin D metabolism. Dysregulation of nagalase is associated with several pathological conditions, including Schindler disease, psychiatric disorders, viral infections, and notably, cancer. Elevated serum levels of nagalase, particularly the Naga6 isoform, have been observed in cancer patients and individuals with enveloped viral infections, contributing to immune evasion by impairing macrophage activation through Gc protein deglycosylation. Moreover, nagalase activity has been implicated in rare blood group changes observed in some malignancies. Although ELISA-based assays offer potential for quantifying nagalase, their clinical application is hindered by assay interferences and cross-reactivity. The immunotherapeutic potential of Gc protein-derived macrophage activating factor (GcMAF), in combination with vitamin D3 and ascorbate, has shown promise in enhancing anti-tumor immunity, particularly in prostate cancer. Nevertheless, conflicting data and methodological criticisms have led to skepticism regarding its efficacy. This review comprehensively explores the biochemical variants of nagalase, its physiological and pathological roles, its diagnostic utility as a biomarker, and emerging therapeutic strategies targeting its activity, including gene silencing and monoclonal antibody development. The findings underscore the need for rigorous clinical studies to validate the diagnostic and therapeutic potential of nagalase in oncology and immunology.